Ribavirin in combination with Peginterferon alfa-2a or Interferon alfa is indicated for the treatment of chronic hepatitis C (CHC) infection in patients 5 years of age and older who have compensated liver disease and have not been previously treated with interferon alfa. Ribavirin should not be used as monotherapy because it is not effective when used alone.

Ribavirin is a synthetic nucleoside with inhibitory activity against respiratory syncytial virus (RSV), influenza virus, and herpes simplex virus. The exact mechanism of action is not fully understood. It is believed to act at multiple sites, including cellular enzymes, to interfere with viral nucleic acid synthesis. The mono- and triphosphate derivatives of Ribavirin are primarily responsible for its antiviral effects.

The recommended duration of treatment for patients previously untreated with Interferon/Peginterferon is 24 to 48 weeks. The daily dose of Ribavirin is 800 mg to 1200 mg administered orally in two divided doses (morning and evening). Genotypes 2 and 3 showed no increased response to treatment beyond 24 weeks.

Special dosage instructions: If severe adverse reactions or laboratory abnormalities develop during therapy with ribavirin, modification of the dosages are required until the adverse reactions abate. Because of the recognized heamolysis associated with ribavirin therapy, separate guidelines are provided for patients with a history of cardiovascular disease.

Use in renal impairment: The total daily dose of Ribavirin should be reduced for patients with creatinine clearance less than or equal to 50 ml/minute.

Use in the elderly ( 65 years of age): There is no sufficient clinical studies about the effectiveness and safety of Ribavirin in combination with interferon alfa or pegylated interferon alfa in these patients.

Use in patients under the age of 5 years: Safety and effectiveness of Ribavirin in combination with interferon alfa or pegylated interferon alfa in these patients have not been evaluated.

Ribavirin should not be used with Didanosine, Zidovudine, or Azathioprine because combining these drugs can increase the risk of serious side effects and reduce treatment safety.

Ribavirin should not be used in patients who have hypersensitivity to the active ingredient or any of the excipients. It is also contraindicated in pregnant women, men whose female partners are pregnant, patients with hemoglobinopathies (such as thalassemia major or sickle cell anemia), autoimmune hepatitis, or hepatic decompensation before or during treatment.

The primary adverse effect of Ribavirin is hemolytic anemia. Patients receiving combination therapy with Interferon alfa or Pegylated Interferon alfa and Ribavirin may experience cough, anxiety, depression, dizziness, nausea, vomiting, flu-like symptoms (such as fever, chills, sore throat, muscle aches), headache, abdominal pain, diarrhea, constipation, chest pain, rapid heart rate (tachycardia), shortness of breath (dyspnea), neutropenia, and thrombocytopenia.

Pregnancy: Ribavirin must not be used by pregnant women or women planning to become pregnant because it may cause birth defects (teratogenic effects). Male patients and their female partners of childbearing age should be advised to use two effective forms of contraception during Ribavirin treatment and for 6 months after completing therapy. Ribavirin should not be started until a negative pregnancy test is confirmed immediately before treatment. Pregnancy tests must also be performed monthly during therapy and for 6 months after therapy.

Breastfeeding: It is unknown whether Ribavirin passes into human breast milk. Due to the risk of adverse reactions in nursing infants, a decision should be made to either stop breastfeeding or avoid starting Ribavirin therapy.

Ribavirin used in combination therapy should be administered under the supervision of a qualified physician experienced in hepatitis C treatment. It may cause moderate to severe adverse reactions that require dose reduction, temporary interruption, or discontinuation of therapy.

Because Ribavirin-induced anemia can worsen cardiac disease, patients should be evaluated before starting therapy and closely monitored during treatment. If cardiovascular status deteriorates, Ribavirin therapy should be suspended or stopped. Patients with pre-existing heart problems should have an electrocardiogram (ECG) before starting Ribavirin.

Common adverse reactions include kidney disease, blood disorders (such as sickle cell anemia or low hemoglobin), autoimmune hepatitis, diabetes, and allergic reactions.

Caution is advised in elderly patients. Before starting therapy, patients should have complete blood count (CBC), differential count, platelet count, electrolytes, serum creatinine, liver function tests, and uric acid measured. After starting Ribavirin therapy, hematological tests should be repeated at 2 and 4 weeks, and biochemical tests at 4 weeks.

Hepatic viral infections (Hepatitis C)

Ribavirin should be stored in a dry place at a temperature not exceeding 30°C, protected from light, and kept out of reach of children.